News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,290 Results
Type
Article (13873)
Company Profile (294)
Press Release (246123)
Section
Business (79324)
Career Advice (150)
Deals (13180)
Drug Delivery (32)
Drug Development (50287)
Employer Resources (31)
FDA (5670)
Job Trends (5114)
News (144064)
Policy (10014)
Tag
Academia (903)
Alliances (21470)
Alzheimer's disease (736)
Approvals (5644)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4498)
Biotechnology (242)
Breast cancer (66)
Cancer (694)
Cardiovascular disease (62)
Career advice (131)
CAR-T (56)
Cell therapy (176)
Clinical research (39809)
Collaboration (238)
Compensation (97)
COVID-19 (1004)
C-suite (68)
Cystic fibrosis (66)
Data (792)
Diabetes (73)
Diagnostics (1200)
Earnings (28974)
Events (46840)
Executive appointments (193)
FDA (5962)
Funding (247)
Gene editing (55)
Gene therapy (147)
GLP-1 (300)
Government (1064)
Healthcare (6536)
Infectious disease (1039)
Inflammatory bowel disease (94)
IPO (7179)
Job creations (859)
Job search strategy (126)
Layoffs (184)
Legal (1373)
Lung cancer (111)
Manufacturing (74)
Medical device (2552)
Medtech (2553)
Mergers & acquisitions (6102)
Metabolic disorders (225)
Neuroscience (946)
NextGen Class of 2024 (1998)
Non-profit (843)
Northern California (947)
Obesity (124)
Opinion (91)
Parkinson's disease (61)
Patents (52)
People (24980)
Pharmaceutical (49)
Phase I (14005)
Phase II (18519)
Phase III (11736)
Pipeline (321)
Postmarket research (846)
Preclinical (5927)
Radiopharmaceuticals (205)
Rare diseases (168)
Real estate (1409)
Regulatory (8201)
Research institute (931)
Southern California (865)
Startups (1964)
United States (7618)
Vaccines (159)
Weight loss (76)
Date
Today (66)
Last 7 days (486)
Last 30 days (2297)
Last 365 days (20703)
2024 (19008)
2023 (22412)
2022 (26823)
2021 (27807)
2020 (23361)
2019 (16226)
2018 (11738)
2017 (13745)
2016 (11840)
2015 (14350)
2014 (10392)
2013 (7485)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16830)
Australia (2837)
California (2148)
Canada (713)
China (163)
Colorado (81)
Connecticut (85)
Europe (36246)
Florida (229)
Georgia (62)
Illinois (126)
Indiana (54)
Kansas (55)
Maryland (300)
Massachusetts (1706)
Michigan (48)
Minnesota (93)
New Jersey (546)
New York (611)
North Carolina (399)
Northern California (947)
Ohio (79)
Pennsylvania (429)
South America (207)
Southern California (865)
Texas (228)
Washington State (219)
260,290 Results for "frontera therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Frontera Therapeutics Doses First Patient in a Trial of FT-002 Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it has dosed the first patient in a clinical trial of its gene therapy product, FT-002.
February 16, 2023
·
3 min read
Genetown
Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD
Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it has dosed the first patient in a clinical trial of its innovative gene therapy product, FT-003, at the Ophthalmology Hospital of Tianjin Medical University in Tianjin, China.
February 2, 2023
·
2 min read
Drug Development
Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2
Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, today announced that it has dosed the first patient in a Phase 1 clinical trial of its lead gene therapy program, FT-001, for the treatment of Leber Congenital Amaurosis-2, a severe inherited retinal disease related to a mutation in the RPE65 gene.
January 6, 2023
·
2 min read
Genetown
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities
Frontera Therapeutics, a clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, today announced successful completion of a $160 million Series B funding round.
July 19, 2022
·
3 min read
Drug Development
Gene Therapy Player Frontera Announces $160M to Drive Four Assets into the Clinic
Frontera Therapeutics closed on a Series B funding round worth $160 million and announced an IND approval by the FDA for rare genetic retinal disease
July 21, 2022
·
3 min read
·
Mark Terry
Business
Money on the Move: Auron, Frontera, Immunocore and More Reel in New Funds (Updated)
Auron Therapeutics reels in $48 million to identify novel AI-based cancer targets, Frontera scoops up $160 million for AAV gene therapy and tech manufacturing and MMI scores $75 million for robotic microsurgery.
July 20, 2022
·
5 min read
·
Hannah Chudleigh
Genetown
Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001China CDE accepts Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease
Frontera Therapeutics today announced that its lead program, FT-001, a gene therapy product candidate targeting inherited retinal degenerations (IRDs) with a RPE65 mutation, successfully obtained an IND from the Center for Drug Evaluation (CDE) , NMPA, in China.
September 21, 2022
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Layoffs
Spero Therapeutics to Lay Off 39% of Employees
Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.
October 30, 2024
·
1 min read
·
Angela Gabriel
1 of 26,029
Next